Condition
Joint pain
8 compounds were checked against joint pain. 4 earned a graded row; the rest are named below.
Last updated
Recorded under Pain, alongside 1 other indication.
Compounds with a graded row
Ordered by rung, strongest first. The rung rates the study design; the chip beside it says what the study measured. Both are needed.
-
Collagen Peptides
human RCT Direct outcome Not approved for this condition
- Who was studied
- adults aged 40-75 with mild to moderate knee osteoarthritis (Kellgren-Lawrence grade I-III), pooled n=507 across 4 randomised placebo-controlled trials; oral hydrolysed collagen peptides 2-10 g daily for 90-180 days
A meta-analysis of four randomised placebo-controlled trials pooled 100 mm visual analogue scale knee pain scores and reported a standardised mean difference of -0.58 (p = 0.004) favouring oral collagen peptides, graded moderate quality. The joint studied is the knee in osteoarthritis; no trial on file measured hip, hand, shoulder or inflammatory arthritis pain, and collagen peptides are a food ingredient with no regulatory approval for joint pain anywhere.
Source PubMed Central 1 primary source read for this row
-
Cartilage Peptides
human case series Direct outcome Not approved for this condition
- Who was studied
- adults with moderate knee joint discomfort and loss of function consistent with osteoarthritis, n=33, 1000 mg fish cartilage hydrolysate orally once daily for 3 months; open-label, no control group
An exploratory, non-comparative, multi-centre open-label study measured the Knee injury and Osteoarthritis Outcome Score and reported improvement in the pain and function subscales. With no placebo arm and no randomisation the improvement cannot be separated from natural course or expectation, and the authors state the result needs confirmation in a randomised controlled trial. The population is knee osteoarthritis only; no data on other joints is on file.
Source PubMed Central 1 primary source read for this row
-
HGH Frag 176-191
animal in vivo Direct outcome Not approved for this condition
- Who was studied
- 32 mature New Zealand white rabbits with collagenase-induced knee osteoarthritis, in four arms: saline, hyaluronic acid, 0.25 mg AOD9604, and AOD9604 plus hyaluronic acid; weekly ultrasound-guided intra-articular injections for 4-7 weeks, assessed at 8 weeks
Lameness duration was measured as well as cartilage histology. The lameness period was shortest in the combined AOD9604 and hyaluronic acid group and longest in the saline group; AOD9604 alone did not beat hyaluronic acid alone on either the histological score or the lameness period. The route is intra-articular injection into a rabbit knee, which is not how the compound is sold or used, and there is no human study of it against joint pain. Rung set from the study's own design wording, "rabbits".
Source PubMed 1 primary source read for this row
-
Hyaluronic Acid Binding Peptide
animal in vivo Direct outcome Not approved for this condition
- Who was studied
- Mice with anterior cruciate ligament transection as a model of post-traumatic osteoarthritis, treated intra-articularly with an HA-binding peptide conjugated to 8-arm PEG and a collagen-binding peptide, against saline and against the clinical hyaluronan comparator Orthovisc, in young and aged animals
Pain was measured directly, by incapacitance and hotplate testing, and was reduced relative to saline; cartilage degeneration by OARSI scoring was also reduced, and in aged mice the peptide-polymer held its effect where the hyaluronan comparator did not. This is a mouse surgical model with no human study on file, and the tested agent is a peptide-polymer conjugate rather than the free peptide. Rung set from the study's own design wording, "in vivo".
Source PubMed 69 primary sources read for this row
Recorded absences
2 compounds are listed here without a rung. Each row exists to mark a distinction a reader would otherwise draw wrongly, and each says what is missing rather than leaving the compound off the page.
-
C-Type Natriuretic Peptide (CNP)
No rung — nothing on file to grade Not approved for this condition
CNP signals through the natriuretic peptide receptor B on growth-plate chondrocytes, and the CNP analogue vosoritide is licensed for bone growth in achondroplasia. Achondroplasia is not a condition in this corpus, and vosoritide is a separate compound from CNP itself. No study of CNP against joint pain exists.
-
IGF-1
No rung — nothing on file to grade Not approved for this condition
No trial of IGF-I against osteoarthritis or any joint pain was found; a targeted search returned nothing.
Checked, and nothing recorded
2 compounds were checked against joint pain and produced no gradeable row.
A compound is here because someone looked and the sources did not support a row — not because nobody looked. Under the rubric, uncertainty resolves to no row, and a row resting on a vendor page or a clinic blog is worse than no row at all.
What this page does not say
It reports what was measured, in whom, and how directly. It does not say what to take or at what dose, and a row here is a record of a study rather than a reason to use anything. Every rung links to the rubric that assigned it.